When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.
A new paper titled “Challenges in Valuing Temporary Health States for Economic Evaluation: A Review of Empirical Applications of the Chained Time Trade-Off Method” has been published in Value in Health.
In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the EQ-5D-3L and EQ-5D-5L; and (4) discuss why those differences might be important. We then (5) explain the next steps, including an independent quality assurance of the value set, and (6) provide an overview of current research projects underway at OHE to provide further evidence on the implications of new value sets for HTA and other uses.